Think Out Loud
NEXT MONTH, THE FOOD AND DRUG ADMINISTRATION COMMITTEE WILL CONSIDER EASING RESTRICTIONS ON SOME PEPTIDES. SOME INFLUENCERS HAVE CLAIMED [https://www.npr.org/2026/02/23/nx-s1-5716162/peptides-science-muscle-growth-longevity-wellness] THESE INJECTABLES IMPROVE MUSCLE GROWTH, CREATE BETTER IMMUNE FUNCTION AND SLOW AGING, AMONG OTHER THINGS. HOWEVER, THERE IS VERY LITTLE EVIDENCE TO SUPPORT THE BENEFITS OF MANY OF THESE DRUGS IN HUMANS. AT THE SAME TIME, PRESCRIPTION PEPTIDES THAT ARE ALREADY ON THE MARKET, SUCH AS GLP-1S LIKE OZEMPIC, HAVE SEEN INCREASING DEMAND [https://www.columbiapsychiatry.org/news/rise-ozempic-sparks-ethical-concerns] FOR OFF-LABEL USE. DANIEL HARTUNG IS A PROFESSOR OF PHARMACY AT OREGON STATE UNIVERSITY. HE JOINS US TO SHARE MORE ON THE FDA PROCESSES AND OFF-LABEL PRESCRIPTIONS.
300 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Think Out Loud!